Literature DB >> 16443603

Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.

Diane Cripps1, Stefani N Thomas, Young Jeng, Frank Yang, Peter Davies, Austin J Yang.   

Abstract

One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of paired helical filaments (PHFs) of hyperphosphorylated microtubule-associated protein Tau. Tandem mass spectrometry was employed to examine PHF-Tau post-translational modifications, in particular protein phosphorylation and ubiquitination, to shed light on their role in the early stages of Alzheimer disease. PHF-Tau from Alzheimer disease brain was affinity-purified by MC1 monoclonal antibody to isolate a soluble fraction of PHF-Tau in a conformation unique to human AD brain. A large number of phosphorylation sites were identified by employing a data-dependent neutral loss algorithm to trigger MS3 scans of phosphopeptides. It was found that soluble PHF-Tau is ubiquitinated at its microtubule-binding domain at residues Lys-254, Lys-311, and Lys-353, suggesting that ubiquitination of PHF-Tau may be an earlier pathological event than previously thought and that ubiquitination could play a regulatory role in modulating the integrity of microtubules during the course of AD. Tandem mass spectrometry data for ubiquitin itself indicate that PHF-Tau is modified by three polyubiquitin linkages, at Lys-6, Lys-11, and Lys-48. Relative quantitative analysis indicates that Lys-48-linked polyubiquitination is the primary form of polyubiquitination with a minor portion of ubiquitin linked at Lys-6 and Lys-11. Because modification by Lys-48-linked polyubiquitin chains is known to serve as the essential means of targeting proteins for degradation by the ubiquitin-proteasome system, and it has been reported that modification at Lys-6 inhibits ubiquitin-dependent protein degradation, a failure of the ubiquitin-proteasome system could play a role in initiating the formation of degradation-resistant PHF tangles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443603     DOI: 10.1074/jbc.M512786200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  111 in total

1.  Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.

Authors:  Eric B Dammer; Chan Hyun Na; Ping Xu; Nicholas T Seyfried; Duc M Duong; Dongmei Cheng; Marla Gearing; Howard Rees; James J Lah; Allan I Levey; John Rush; Junmin Peng
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

2.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 3.  Characterizing ubiquitination sites by peptide-based immunoaffinity enrichment.

Authors:  Daisy Bustos; Corey E Bakalarski; Yanling Yang; Junmin Peng; Donald S Kirkpatrick
Journal:  Mol Cell Proteomics       Date:  2012-06-23       Impact factor: 5.911

4.  Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg.

Authors:  Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Acetylation of tau inhibits its degradation and contributes to tauopathy.

Authors:  Sang-Won Min; Seo-Hyun Cho; Yungui Zhou; Sebastian Schroeder; Vahram Haroutunian; William W Seeley; Eric J Huang; Yong Shen; Eliezer Masliah; Chandrani Mukherjee; David Meyers; Philip A Cole; Melanie Ott; Li Gan
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

6.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

7.  FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.

Authors:  Waltraud Mair; Jan Muntel; Katharina Tepper; Shaojun Tang; Jacek Biernat; William W Seeley; Kenneth S Kosik; Eckhard Mandelkow; Hanno Steen; Judith A Steen
Journal:  Anal Chem       Date:  2016-03-07       Impact factor: 6.986

8.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 9.  Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma.

Authors:  Hussein Abou-Abbass; Hadi Abou-El-Hassan; Hisham Bahmad; Kazem Zibara; Abir Zebian; Rabab Youssef; Joy Ismail; Rui Zhu; Shiyue Zhou; Xue Dong; Mayse Nasser; Marwan Bahmad; Hala Darwish; Yehia Mechref; Firas Kobeissy
Journal:  Electrophoresis       Date:  2016-04-04       Impact factor: 3.535

10.  Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease.

Authors:  Stefani N Thomas; Diane Cripps; Austin J Yang
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.